This is highly despicable as it's pretty much guaranteed that some people will die from not being able to afford the med. The market is not as efficient as we'

This is highly despicable as it's pretty much guaranteed that some people will die from not being able to afford the med. The market is not as efficient as we'd like to think. In a perfect libertarian world, another company pops up and competes to drive the prices down. However, even if the IP of the drug itself is public domain, there's a cost to ramp up a new production line, all for a product which has low intrinsic value commercially. Shkreli purposely selected a drug that's needed enough (so guaranteed demand) but whose market is not too large, preventing bigger companies from jumping in. (And I'm ignoring for the moment his tactic to tightly secure the supply chain, essentially trying to build a little moat around this product.) This puts would-be competitors in a tough spot, where the risk is to invest in setting up the manufacturing line, only to have the original company drop the price again and ensure they won't be able to recover their cost. For the sake of the patients, I can only hope there are generic makers who go for it anyway.